New Method to Assist Fast-Tracking of Vaccines for Pre-Clinical Tests

Joint lead author Dr. Anneliese Ashhurst from the School of Chemistry at the University of Sydney. Courtesy of University of Sydney

Scientists in Australia have developed a method for the rapid synthesis of safe vaccines, an approach that can be used to test vaccine strategies against novel pandemic pathogens such as SARS-CoV-2, the virus that causes COVID-19.

Led by professor Richard Payne at the University of Sydney and professor Warwick Britton at the Centenary Institute, the team has demonstrated application of the method with a new vaccine for use against tuberculosis (TB), which has generated a powerful protective immune response in mice.

Researchers are keen to develop the vaccine strategy further to assist in the rapid pre-clinical testing of new vaccines, particularly for respiratory illnesses.

"Tuberculosis infects 10 million and kills more than 1.4 million people every year," said joint first author Dr. Anneliese Ashhurst from the University of Sydney. "Historically, it is the leading cause of death worldwide from a single infectious agent. So far, a TB vaccine that is highly effective and safe to use in all populations has eluded medical science."

The only current vaccine for tuberculosis, the Bacille Calmette-Guerin vaccine, uses an injected live bacterium. It is effective in infants but has reduced effectiveness in adolescents and adults and poses significant health risks for immunocompromised patients, particularly for people living with HIV/AIDS.

Protein-based vaccines have been shown to be very safe, but they must be mixed with enhancers, or adjuvants, to make them effective, which is not straightforward.

Ashhurst said, "The challenge is to ensure that our immune cells see both the protein and adjuvant simultaneously. To overcome this difficulty, for the first time we have developed a method that synthesises the protein with an attached adjuvant as a single molecule."

The vaccine strategy and synthetic technology could be deployed to rapidly generate new vaccines for pre-clinical testing for a range of diseases, the researchers say, including the respiratory pathogen that causes COVID-19.

Their results are published today in the Proceedings of the National Academy of Sciences.

In order for vaccines to be effective, they need to stimulate behavior in protective T-cells that allows them to recognise the pathogen as an antigen, or foreign body. In the case of tuberculosis, our immune system needs to respond quickly to the bacteria that causes TB - Mycobacterium tuberculosis - to reduce infection in lungs.

Using the method developed by the Sydney scientists, an inhaled vaccine provides a low-dose immune-stimulating molecule - containing a synthesized bacterial protein attached directly to an adjuvant - to the immune cells in the lungs.

A major hurdle overcome by the scientists was the difficulty in fusing hydrophobic (water-repellent) adjuvants with a water-soluble protein antigen.

"We got around this problem of keeping hydrophobic and hydrophilic molecules together in a vaccine by developing a way to permanently bind the protein and adjuvant together as a single molecule using synthetic chemistry. Our approach overcomes the solubility problems faced by other methods," said Professor Payne from the School of Chemistry and Deputy Director of the ARC Centre for Innovations in Peptide & Protein Science (CIPPS).

The team says that synthesizing an entire bacterial protein with attached adjuvant has not been achieved before.

Professor Britton from the Tuberculosis Research Program at the Centenary Institute said: "As well as providing a rapid method to develop a range of vaccines for pre-clinical testing, we expect that this pulmonary vaccination approach will be particularly beneficial for protecting against respiratory diseases."

He said: "We hope that an inhaled vaccine for tuberculosis using a protein-based immunization will allow us to develop a universal and safe approach to combatting this deadly disease."

The other major advantage with this method is that vaccines for a range of diseases can be developed rapidly and safely in the laboratory.

"We don't need to grow the actual pathogen in the lab to make the vaccine," said Ashhurst, who holds a joint position in the School of Chemistry and the School of Medical Sciences. "Using this new method, we can rapidly and safely synthesize highly pure vaccines in the lab and take them straight into animal models for pre-clinical testing."

Source: University of Sydney

 

8 Comments on "New Method to Assist Fast-Tracking of Vaccines for Pre-Clinical Tests"

  1. 265343 520291I admire your piece of work, regards for all the intriguing posts . 780859

  2. yeah bookmaking this wasnt a high risk determination outstanding post! .

  3. Hi there, MegaCool blog mate, I really loved this page. I’ll be sure to talk about this to my cousin who would, odds are, love to check out this post too. Found this sites post through the Bing search engine by the way, incase you were curious. Many thanks for the wonderful read!

  4. 578979 437899As I site owner I feel the topic material here is real fantastic, appreciate it for your efforts. 531891

  5. 335280 554235Real informative and wonderful anatomical structure of topic material , now thats user pleasant (:. 843954

  6. hello there! thanks for posting this. I appreciate your point of view and I see where youre coming from. thanks again!

  7. 130794 7856I totally agree! I came more than from google and am seeking to subscribe. Exactly where is your RSS feed? 142351

  8. Hi. I just noticed that your site looks like it has a few code errors at the very top of your websites page. Im not sure if everybody is getting this same problem when browsing your site? I am employing a totally different browser than most people, referred to as Opera, so that is what might be causing it? I just wanted to make sure you know. Thanks for posting some great postings and Ill try to return back with a completely different browser to check things out!

Leave a comment

Your email address will not be published.


*